Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage
Completed
- Conditions
- Type 2 Diabetes
- Registration Number
- NCT01275794
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is assessment of glycemic control and physicians satisfaction with results of DM2 OAD monotherapy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1849
Inclusion Criteria
- Patients have an established diagnosis of T2D
- Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
Exclusion Criteria
- Experience of therapy with two or more OADs and/or insulin therapy and/or incretin mimetics (exenatide) at any time before registration in the Program
- Absence of changes in HbAc1 level during the last year before registration in the Program
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess levels of compensation of T2D by HbA1c levels in patients on OAD monotherapy 1 visit within 4 month To assess frequency of target levels of HbA1c ≤ 7% in patients with T2D during OAD monotherapy 1 visit within 4 month
- Secondary Outcome Measures
Name Time Method To assess fasting glycemia in patients with T2D on OAD monotherapy 1 visit within 4 month To assess postprandial levels of glycemia in patients with T2D during OAD monotherapy 1 visit within 4 month To evaluate the physicians' satisfaction with the results of OAD monotherapy in patients with Typ 2 Diabetes (T2D) 1 visit within 4 month To compare the results of OAD monotherapy in different groups of patients 1 visit within 4 month
Trial Locations
- Locations (1)
Research Site
🇷🇺Yaroslavl, Russian Federation